Elsevier

Biological Psychiatry

Volume 55, Issue 10, 15 May 2004, Pages 1013-1022
Biological Psychiatry

Original article
A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: opening a closed book

https://doi.org/10.1016/j.biopsych.2004.01.027Get rights and content

Abstract

Background

In recent years, numerous studies have examined whether new-generation antipsychotic agents impact cognitive impairment in patients with schizophrenia when compared with conventional antipsychotic treatment. The working assumption of such studies, supported by narrative reviews, is that the conventional antipsychotic medications have little or no effect on cognition. The studies concerning the effects of conventional neuroleptics on cognition, however, have never been analyzed quantitatively. In this meta-analysis, we revisit the question of whether typical agents might have enhancing effects on cognition.

Methods

The meta-analysis included studies that 1) compared the effects of typical neuroleptic agents with those of placebo or no medication on cognition; 2) examined adult patients identified as having schizophrenia; and 3) produced adequate data to estimate an effect size. Studies were identified by searches of computerized literature databases and by cross-referencing included studies. The effect size calculated was d, the difference between the means in cognitive measures of patients with schizophrenia taking and not taking conventional neuroleptic medication, divided by the pooled SD. Critically, when multiple measures were reported in a single article, effect sizes were combined so as to minimize the possibility that one study had undue weight simply because of the number of cognitive outcome variables that it contained. These results were corrected for bias due to sample size, with each of the effect sizes weighted by the reciprocal of its variance. The final sample after exclusion of outliers comprised 208 effect sizes from 34 studies.

Results

With a random-effects model, effect sizes from the primary studies were weighted according to sample size and averaged. The resulting mean effect size was .22 (95% confidence interval = .10, .34). The result is positive, in that the range did not include zero and was of low moderate size. No moderating effects of study design or patient qualities were found to be significant. With the same procedures, effect sizes for individual neurocognitive domains were computed. Effect sizes were generally in the .13–.29 range for the majority of cognitive functions, whereas motor function was impacted negatively (−.11). Unexpectedly, medication dose did not correlate with effect size.

Conclusions

Typical antipsychotic medication provides modest-to-moderate gains in multiple cognitive domains. Given unavoidable methodologic limitations of the primary studies, current findings suggest that the impact of conventional medication on cognitive function should be re-evaluated.

Section snippets

Identification of studies

To examine the effects of conventional neuroleptic medication on the cognition of patients with schizophrenia, we endeavored to locate all studies that examined the impact of antipsychotic medication on some aspect of cognition with a generally acceptable cognitive, neuropsychological, or information-processing measure by comparing the performance of patients taking and not taking medication (i.e., with a placebo arm). The corpus of primary studies was limited to those studies that compared

Results

Initially, 224 effect sizes were obtained from data extracted from 36 articles, including 26 effect sizes from studies that were estimated from t, F, or p values. Some primary studies (Gilbertson and van Kammen, 1997, Killian et al., 1984, Oltmanns et al., 1978) conducted between-subjects and within-subject comparisons with the same subjects. To not give undue weight to such studies, we computed effect sizes in these cases from the between-group comparisons because the majority of studies in

Discussion

Contrary to conventional wisdom and some narrative reviews, including our own (Goldberg and Gold, 1995, Goldberg and Weinberger, 1996), typical antipsychotic medication provides modest to moderate gains in most cognitive domains tested in patients with schizophrenia. This enhancing effect did not rest on outlier studies, study qualities involving subject allocation, the blind, patient characteristics, or discernible aspects of subjects' clinical status. The results were not artifacts of

References (108)

  • S.R Marder et al.

    Information processing and neuroleptic response in acute and stabilized schizophrenic patients

    Psychiatry Res

    (1984)
  • A Medalia et al.

    The effects of neuroleptics on neuropsychological test results of schizophrenics

    Arch Clin Neuropsychol

    (1988)
  • A.M Mortimer

    Cognitive function in schizophrenia—do neuroleptics make a difference?

    Pharmacol Biochem Behav

    (1997)
  • T.F Oltmanns et al.

    The effect of antipsychotic medication and diagnostic criteria on distractibility in schizophrenia

    J Psychiatry Res

    (1978)
  • J.A Sweeney et al.

    Relationships between medication treatments and neuropsychological test performance in schizophrenia

    Psychiatr Res

    (1991)
  • H Allain et al.

    Comparative effects of pharmacotherapy on the maintenance of cognitive function

    Eur Psychiatry

    (2001)
  • Practice Guideline for the Treatment of Patients with Schizophrenia

    (1997)
  • H.V Angel

    Role of chlorpromazine in maintaining timing behavior in schizophrenics

    Psychopharmocologica

    (1973)
  • R.R Baker

    The effects of psychotropic drugs on psychological testing

    Psychol Bull

    (1968)
  • D.M Barch et al.

    Semantic priming in schizophreniaAn examination of spreading activation using word pronunciation and multiple SOA's

    J Abnorm Psychol

    (1996)
  • M.A Bedard et al.

    Differential effects of D-2 and D-4 blocking neuroleptics on the procedural learning of schizophrenic patients

    Can J Psychiatry

    (1996)
  • R.M Bilder et al.

    Antipsychotic medication effects on neuropsychological functions

    Psychopharmacol Bull

    (1992)
  • C.R Blyler et al.

    Cognitive effects of typical antipsychotic treatmentAnother look

  • P Bollini et al.

    Antipsychotic drugsIs more worse? A meta-analysis of the published randomized control trials

    Psychol Med

    (1994)
  • M Borenstein et al.

    Comprehensive Meta-AnalysisA Computer Program for Research Synthesis

    (1999)
  • D.L Braff et al.

    Effect of antipsychotic medication on speed of information processing in schizophrenic patients

    Am J Psychiatry

    (1982)
  • A Breier et al.

    National Institute of Mental Health longitudinal study of chronic schizophrenia. Prognosis and predictors of outcome

    Arch Gen Psychiatry

    (1991)
  • A Calev

    Recall and recognition in mildly disturbed schizophrenicsThe use of matched tasks

    Psychol Med

    (1984)
  • E Callaway

    Schizophrenia and inference. An analogy with a malfunctioning computer

    Arch Gen Psychiatry

    (1970)
  • G Cassens et al.

    NeurolepticsEffects on neuropsychological function in chronic schizophrenic patients

    Schizophr Bull

    (1990)
  • L Chapman et al.

    Disordered Thought in Schizophrenia

    (1973)
  • J Cohen

    Statistical Power Analysis for the Behavioral Sciences

    (1988)
  • T.J Crawford et al.

    Saccadic abnormalities in psychotic patientsII. The role of neuroleptic treatment

    Psychol Med

    (1995)
  • F Curtin et al.

    Meta-analysis combining parallel and cross-over clinical trials, IIIThe issue of carry-over

    Stat Med

    (2002)
  • P.G Daston

    Effects of two phenothiazine drugs on concentrative attention span of chronic schizophrenics

    J Clin Psychol

    (1959)
  • D.A Drachman

    Memory and the cholinergic system

  • W.P Dunlap et al.

    Meta-analysis of experiments with matched groups or repeated measures designs

    Psychol Methods

    (1996)
  • S Duval et al.

    Trim and fillA simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis

    Biometrics

    (2000)
  • M Egger et al.

    Bias in meta-analysis detected by a simple, graphical test

    BMJ

    (1997)
  • N Eitan et al.

    Effects of antipsychotic drugs on memory functions of schizophrenic patients

    Acta Psychiatr Scand

    (1992)
  • W.D Erickson et al.

    The effects of neuroleptics on attention in adolescent schizophrenics

    Biol Psychiatry

    (1984)
  • B Elvevåg et al.

    Cognitive impairment in schizophrenia is the core of the disorder

    Crit Rev Neurobiol

    (2000)
  • Faustman WO, Hoff AL (1996): Effects of antipsychotic drugs on neuropsychological measures. In: Csernasky JG, editor....
  • K Flekkoy

    Changes in associative performance in hospitalized schizophrenicsA sixteen-year follow-up

    Acta Psychiatr Scand

    (1975)
  • Flekkoy K, Astrup C, Hartmann (1969): Word associations in schizophrenics: A ten-year follow-up. Acta Psychiatr Scand...
  • C.D Frith

    Schizophrenia, memory, and anticholinergic drugs

    J Abnorm Psychol

    (1984)
  • R Galbraith

    A note on graphical representation of estimated odds ratios from several clinical trials

    Stat Med

    (1988)
  • J Geddes et al.

    Atypical antipsychotics in the treatment of schizophreniaSystematic overview and meta-regression analysis

    BMJ

    (2000)
  • C.A Gilgash

    Effects of thorazine on Wechsler scores of adult catatonic schizophrenics

    Psychol Rep

    (1957)
  • G.V Glass et al.

    Meta-Analysis in Social Research

    (1981)
  • Cited by (275)

    • Antipsychotics: Mechanisms underlying clinical response and side-effects and novel treatment approaches based on pathophysiology

      2020, Neuropharmacology
      Citation Excerpt :

      Up to 80% of patients with schizophrenia have some form of cognitive impairment (Reichenberg et al., 2009), which may predate the onset of schizophrenia (Bora and Murray, 2014) and is associated with poor outcomes (Green, 2016). Antipsychotics improve cognitive functioning in first episode and chronic patients when cognitive testing is repeated over time, but there seems to be little difference between agents and some patients show limited improvement (Davidson et al., 2009; Keefe et al., 2007; Mishara and Goldberg, 2004; Nielsen et al., 2015; Woodward et al., 2005). Molecular imaging studies have linked dopaminergic function to performance on cognitive tasks.

    View all citing articles on Scopus
    View full text